Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

53 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-01-31

Study Completion Date

2020-11-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chemotherapy induced diarrhea is seen in up to 40-80% of patients receiving this treatment for HER2 positive locally advanced or metastatic breast cancer. This diarrhea can significantly impact a patient's quality of life and ability to tolerate chemo/anti-HER2 therapy. This study will look at the efficacy of the drug crofelemer in preventing diarrhea in breast cancer patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib

NCT03094052

HER2-positive Breast Cancer Breast Adenocarcinoma Stage II Breast Cancer AJCC v6 and v7 +6 more

COMPLETED PHASE2

Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer

NCT02294786

Cancer

TERMINATED PHASE2

Lapatinib Resistance in Patients With Breast Cancer

NCT00898573

Breast Cancer

WITHDRAWN

Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer

NCT01281163

Estrogen Receptor Negative Estrogen Receptor Positive HER2/Neu Positive +4 more

TERMINATED PHASE1

Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer

NCT00049114

Inflammatory Breast Cancer Stage II Breast Cancer Stage IIIA Breast Cancer +2 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Various anti-diarrheal agents, such as loperamide, codeine, octreotide, are available for diarrhea management, but few are used in the prophylactic setting and none provide a targeted approach for treating chemotherapy induced diarrhea (CID).

Pre-clinical studies have suggested that blocking EGFR results in excess chloride secretion and thus diarrhea. Crofelemer is an extract from the blood red bark of Croton lechleri that inhibits luminal chloride efflux by blocking the calcium activated chloride channel (CaCC) and cystic fibrosis transmembrane regulator (CFTR) chloride channels. Due to its size and polarity, it acts only luminally and is not systemically absorbed. It is currently FDA approved for use in preventing diarrhea in HIV/AIDS patients on anti-retroviral therapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Crofelemer

Patients on the treatment arm will take one tablet of crofelemer twice a day (each tablet is 125 mg), to be swallowed whole without chewing or crushing, during cycles 1-2 of chemotherapy with THP or TCHP. Patient will be monitored off crofelemer during cycle 3 of chemotherapy.

Group Type EXPERIMENTAL

Crofelemer

Intervention Type DRUG

Crofelemer 125 mg BID during cycles 1-2 of THP or TCHP

Control

Patients on the control arm will be on the study for cycles 1-3 of THP or TCHP. Patients on the control arm will not receive crofelemer at any time on this study.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Crofelemer

Crofelemer 125 mg BID during cycles 1-2 of THP or TCHP

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Willing and able to provide written informed consent;
2. Men and women ≥18 years of age;
3. Pathologically confirmed diagnosis of HER2 positive breast cancer of any stage (previous treatment is allowed without limits on lines of prior therapy);
4. Scheduled to receive at least 3 consecutive cycles of THP or TCHP;
5. Performance status of 0-2 according to the ECOG scale;
6. Negative pregnancy test at time of informed consent for women of childbearing potential;
7. Able to read, understand, follow the study procedure and complete crofelemer, rescue medication, and bowel movement diaries;
8. Patients may enroll simultaneously on this study and other studies, including but not limited to NSABP B52;
9. Patients with brain metastases (including concurrent steroid treatment) are allowed on this study.
10. Left Ventricular Ejection Fraction (LVEF) greater or equal to 50% at baseline as determined by either ECHO or MUGA

Exclusion Criteria

1. Pregnant and/or breastfeeding;
2. Ongoing irritable bowel syndrome (IBS) or colitis (including but not limited to ulcerative colitis, Crohn's disease, microscopic colitis, etc.);
3. Use of investigational drugs within 3 weeks of signing consent or foreseen use during the study;
4. Use of chemotherapy, trastuzumab, or pertuzumab within the past 3 weeks;
5. Use of antibiotics within the past 7 days (up to 2 prophylactic doses of antibiotics for procedures including, but not limited to port placement, is permitted);
6. Any type of ostomy;
7. Total colectomy;
8. Fecal incontinence;
9. Ongoing radiation induced diarrhea or constipation or planned radiotherapy to the abdomen or pelvis while on study;
10. Active systemic infection requiring ongoing intervention, including but not limited to oral and intravenous antibiotics, anti-fungals, anti-parasites, anti-virals;
11. Abdominal or pelvic surgery without recovery of bowel function;
12. Inadequate organ function for starting THP or TCHP, which may include the following laboratory results within 28 days prior to signing consent:

1. Total bilirubin \> upper limit of normal (ULN) (unless the patient has documented Gilbert's syndrome)
2. Serum creatinine \> 2.0 mg/dL or 177 μmol/L
3. AST (SGOT) and ALT (SPGT) \> 2.5 ULN.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No